Key regions: Brazil, India, Australia, United States, United Kingdom
The demand for antiviral drugs has been on the rise in Turkey due to various factors.
Customer preferences: Turkish consumers are increasingly becoming health-conscious and are taking preventive measures to avoid illnesses. The COVID-19 pandemic has also played a significant role in increasing the demand for antiviral drugs in Turkey. Consumers are now more aware of the importance of maintaining good health and are willing to invest in antiviral drugs to boost their immune systems.
Trends in the market: The antiviral drugs market in Turkey has been experiencing steady growth in recent years. The market is expected to continue growing as the demand for antiviral drugs increases. The market is also witnessing an increase in the number of players, both domestic and international, which is leading to increased competition in the market. This competition is driving innovation and leading to the development of new and more effective drugs.
Local special circumstances: Turkey has a large population of elderly citizens who are more susceptible to illnesses. This has led to an increase in demand for antiviral drugs, especially during the flu season. The country also has a high incidence of chronic illnesses such as diabetes, which can weaken the immune system and make individuals more susceptible to infections. These factors have contributed to the growth of the antiviral drugs market in Turkey.
Underlying macroeconomic factors: The Turkish government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare services and drugs. The government has also been implementing policies to encourage the growth of the pharmaceutical industry in the country. These policies have attracted foreign investment, which has further boosted the growth of the antiviral drugs market. The Turkish economy has also been growing steadily, which has led to an increase in disposable income among consumers. This has led to an increase in demand for high-quality healthcare services and drugs, including antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
